The interpretation of 131i scans in the evaluation of thyroid cancer, with an emphasis on false positive findings

Nuclear Medicine Communications

Volumn 24, Issue 6, 2003, Pages 715-735

  Carlisle, M R ^a   Lu, C ^a   McDougall, I Ross ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

False positive; Radioiodine scan; Thyroid cancer

Indexed keywords

DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; CASE REPORT; CHILD; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MALE; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DIAGNOSIS, DIFFERENTIAL; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 0242438701     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200306000-00015     Document Type: Review

References (107)

1. Spitzweg C, Heufelder AE, Morris JC. Thyroid iodine transport. Thyroid 2000; 10: 321-330.
2. De La Vieja A, Dohan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000; 80: 1083-1105.
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
4. Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnant patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26: 6-9.
5. Britton KE, Foley RR, Siddiqi A, et al. I-123 imaging for the prediction of I-131 therapy for recurrent differentiated thyroid cancer, RDTC, when 1-131 tracer is negative but raised thyroglobulin, Tg. Eur J Nucl Med 1999; 26: 1013.
6. Abdel-Dayem HM, Halker K, Sayed ME. The radioactive wig in iodine-131 whole body imaging. Clin Nucl Med 1984; 9: 454-455.
7. Achong DM, Oates E, Lee SL, Doherty FJ. Gallbladder visualization during post-therapy iodine-131 imaging of thyroid carcinoma. J Nucl Med 1991; 32: 2275-2277.
8. Acosta J, Chitkara R, Khan F, Azueta V, Silver L. Radioactive iodine uptake by a large undifferentiated bronchogenic carcinoma. Clin Nucl Med 1982; 7: 368-369.
9. 131I uptake at a tracheostomy site. Discernment with Tl-201 imaging. Clin Nucl Med 1994; 19: 619-621.
10. Muratet JP, Giraud P. Thymus accumulation of I-131 after therapeutic dose for thyroid carcinoma. Clin Nucl Med 1996; 21: 736-737.
11. 131I uptake in the breast for thyroid cancer surveillance with biopsy-proven benign tissue. Clin Nucl Med 1998; 23: 585-587.
12. Bajramovic S, DeGroot LJ. Spurious metastasis on whole body scans in a patient with thyroid carcinoma. J Endocrinol Invest 1998; 21: 541-543.
13. Bakheet SM, Hammami M. Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med 1994; 21: 604-608.
14. Bakheet SM, Hammami MM. False-positive radioiodine whole-body scan in thyroid cancer patients due to unrelated pathology. Clin Nucl Med 1994; 19: 325-329.
15. Bakheet SM, Powe J, Hammami MM. Radioiodine uptake in the chest. J Nucl Med 1997; 38: 984-986.
16. Berquist TA, Nolan NG, Stephens DM, Carlson HC. Radioisotope scintigraphy in Barrett’s esophagus. Am J Roentgenol 1975; 123: 401-411.
17. Bestagno M, Pagliaini R, Maira G, Pizzocaro C. Mediastinal uptake of 131-I in patients with thyroid cancer: may it be referred to normal thymus? (Letter). Eur J Nucl Med 1993; 20: 648.
18. 131I scan induced by Zenker’s diverticulum. Clin Nucl Med 1992; 17: 243-244.
19. Boxen I, Mei Zhang Z. Nasal secretion of iodine-131. Clin Nucl Med 1989; 14: 610.
20. Brachman MB, Rothman BJ, Ramanna L, Tanasescu DE, Adelberg H, Waxman AD. False-positive iodine-131 body scan caused by large renal cyst. Clin Nucl Med 1988; 13: 416-418.
21. 123I in a Warthin’s tumor. Clin Nucl Med 1978; 3: 155-156.
22. Camponovo EJ, Goyer PF, Silverman ED, Kistler AM, Yudt WM. Axillary iodine-131 accumulation due to perspiration. Clin Nucl Med 1989; 14: 762-763.
23. Caplan RH, Gundersen GA, Abellera RM, Kisken WA. Uptake of iodine-131 by a Meckel’s diverticulum mimicking metastatic thyroid carcinoma. Clin Nucl Med 1987; 12: 760-762.
24. 131I in the biliary tract: a potential cause of a false positive scintiscan. Clin Nucl Med 1998; 23: 524-527.
25. 131I on diagnostic whole-body scan. Clin Nucl Med 2000; 25: 895-897.
26. Ceccarelli C, Pacini F, Lippi F, Pinchera A. An unusual case of a false-positive iodine-131 whole body scan in a patient with papillary thyroid cancer. Clin Nucl Med 1988; 13: 192-193.
27. 131I whole body scan due to contaminated handkerchief. Clin Nucl Med 1989; 14: 301-302.
28. 131I ablation. Clin Nucl Med 1999;: 182-183.
29. Davidson J, McDougall IR. How frequently is the thymus seen on whole-body iodine-131 diagnostic and post-treatment scans. Eur J Nucl Med 2000; 27: 425-430.
30. Dhawan VM, Kaess KR, Spencer RP. False positive thyroid scan due to Zenker’s diverticulum. J Nucl Med 1978; 19: 1231-1232.
31. 131I whole-body scan in follicular thyroid carcinoma caused by frontal sinus mucocele. Clin Nucl Med 2000;: 137-138.
32. Fernandez-Ulloa M, Maxon HR, Mehta S, Sholiton LJ. Iodine-131 uptake by primary lung adenocarcinoma. JAMA 1976; 236: 857-858.
33. Feuerstein IM, Harbert JC. Hypertophied thyroid tissue in a thyroglossal duct remnant. Clin Nucl Med 1986; 11: 135.
34. Francese C, Schlumberger M, Vera JP, Caillou B, Parmentier C. Iodine-131 uptake in a pleuropericardial cyst: case report of a false-positive radioiodine total body scan result in a patient with thyroid cancer. Eur J Nucl Med 1991; 18: 779-780.
35. Giuffrida D, Fornito MC, Pellegriti G, Regalbuto C, Vigneri G. False positive 131-I total body scan due to bilateral polycystic renal disease. J Endocrinol Invest 1997; 20: 342-344.
36. Greenler DP, Klein HA. The scope of false-positive iodine-131 images for thyroid cancer. Clin Nucl Med 1984; 14: 111-117.
37. 131I therapy. Clin Nucl Med 1993; 18: 115-117.
38. Hays MT. Colonic excretion of iodide in normal human subjects. Thyroid 1993; 3: 31-39.
39. Herzog G, Kisling G, Bekerman C. Diagnostic significance of dental history in the clinical evaluation of patients with thyroid carcinoma. Clin Nucl Med 1992; 17: 589-590.
40. Ho Y, Hicks R. Hiatus hernia: a potential cause of false-positive iodine-131 scan in thyroid carcinoma. Clin Nucl Med 1998; 23: 621-622.
41. Hoschl R, Choy DHL, Gandevia B. Iodine-131 uptake in inflammatory lung disease: a potential pitfall in treatment of thyroid carcinoma. J Nucl Med 1988; 29: 701-706.
42. Ibis E, Wilson CR, Collier D, et al. Iodine-131 contamination from thyroid cancer patients. J Nucl Med 1992; 33: 2110-2115.
43. Jackson GL, Graham UY. Thymus accumulation of radioactive iodine. Pa Med 1979; 82: 37-38.
44. 131I uptake in a benign serous cystadenoma of the ovary. Eur J Nucl Med 1984; 9: 433-435.
45. 131I at tracheostomy site on a total body scan. Clin Nucl Med 1984; 9: 409-411.
46. Kistler AM, Yudt WM, Bakalar RS, et al. Retained esophageal activity on iodine-131 survey in patient with benign esophageal stricture. Clin Nucl Med 1993; 18: 908-909.
47. Kolla IS, Alazaraki NP, Watts NB. Sialoadenitis mimicking metastatic thyroid carcinoma. Clin Nucl Med 1989; 14: 564-566.
48. Konez O, Hanelin LG, Jenison EL, Goyal M, Randolph W. Functioning liver metastases on a whole-body scan: a case of maligant struma ovarii. Clin Nucl Med 2000; 25: 465-466.
49. Maslack MM. Iodine-131 accumulation in a pericardial effusion. J Nucl Med 1987; 28: 133.
50. Matheja P, Lerch H, Schmid KW, Kuwert T, Schober O. Frontal sinus mucocele mimicking a metastasis of papillary thyroid carcinoma. J Nucl Med 1997; 38: 1022-1024.
51. McDougall IR. Whole-body scintigraphy with radioiodine-131. A comprehensive list of false-positives with some examples. Clin Nucl Med 1995; 20: 869-875.
52. Michigishi T, Mizukami Y, Shuke N, et al. Visualization of the thymus with therapeutic doses of radioiodine in patients with thyroid cancer. Eur J Nucl Med 1993; 20: 75-79.
53. Misaki T, Takeuchi R, Miyamoto S, Kasagi K, Matsui Y, Konishi J. Radioiodine uptake by squamous cell carcinoma of the lung. J Nucl Med 1994; 35: 474-475.
54. 131I whole body scans in thyroid cancer. Br J Radiol 2000; 73: 627-635.
55. Nichiyama Y, Yamamoto Y, Takahashi K, et al. False-positive iodine-131 whole-body imaging due to gestational sac. Clin Nucl Med 1998; 23: 535-536.
56. Norby EH, Neutze J, van Nostrand D, Burman KD, Warren RW. Nasal radioiodine activity: a prospective study of frequency, intensity and pattern. J Nucl Med 1990; 31: 52-54.
57. Park HM, Tarver RD, Schauwecker DS, Burt R. Spurious thyroid cancer metastases: Saliva contamination artifact in high dose iodine-131 metastases survey. J Nucl Med 1996; 27: 634-636.
58. 131I sodium iodide thyroablation therapy. Clin Nucl Med 1992; 17: 130-131.
59. 131I imaging for metastatic thyroid carcinoma. Clin Nucl Med 1990; 15: 491-494.
60. 131I by a papillary meningioma. Am J Roentgenol 1977; 129: 349-350.
61. Rieser GD, Ober KP, Cowan RJ, Cordell AR. Radioiodine imaging of struma cordis. Clin Nucl Med 1988; 13: 421-422.
62. Rosenbaum RC, Johnston GS, Valente WA. Frequency of hepatic visualization during I-131 imaging of metastatic thyroid carcinoma. Clin Nucl Med 1988; 13: 657-660.
63. Salvatori M, Saletnich I, Rufini V, Troncone L. Unusual false-positive radioiodine whole-body scans in patients with differentiated thyroid carcinoma. Clin Nucl Med 1997; 22: 380-384.
64. Schneider JA, Divgi CR, Scott AM, et al. Hiatal hernia on whole-body radioiodine survey mimicking metastatic thyroid cancer. Clin Nucl Med 1993; 18: 751-753.
65. 131I whole-body imaging. Clin Nucl Med 1998; 23: 334.
66. Serafini A, Sfakianakis G, Georgiou M, Morris J. Breast cyst simulating metastases on iodine-131 imaging in thyroid carcinoma. J Nucl Med 1998; 39: 1910-1912.
67. Shapiro B, Rufini V, Jarwan A, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med 2000; 30: 115-132.
68. Vermiglio F, Baudin E, Travagli JP, et al. Iodine concentration by the thymus in thyroid carcinoma. J Nucl Med 1996; 37: 1830-1831.
69. Veronikis IE, Simkin P, Braverman LE. Thymic uptake of iodine-131 in the anterior mediastinum. J Nucl Med 1996; 37: 991-992.
70. Wadhwa SS, Mansberg R. Benign oral disease as a cause of false-positive iodine-131 scans. Clin Nucl Med 1998; 23: 747-749.
71. 131I by an abdominal neurilemoma mimicking metastatic thyroid carcinoma. Clin Nucl Med 1993; 18: 964-966.
72. 131I in a hiatal hernia mimicking recurrence of papillary thyroid carcinoma. Clin Nucl Med 1993; 18: 961-963.
73. Wilson LM, Barrington SF, Morrison ID, Kettle AG, O’Doherty MJ, Coakley AJ. Therapeutic implications of thymic uptake of radioiodine in thyroid carcinoma. Eur J Nucl Med 1998; 25: 622-628.
74. Wiseman J. Bony metastases from thyroid carcinoma or contamination. Clin Nucl Med 1984; 9: 963.
75. Wu S-Y, Brown T, Milne N, et al. Iodine 131 total body scan - Extrathyroidal uptake of radioiodine. Semin Nucl Med 1986; 16: 82-84.
76. Wu SY, Kollin J, Coodley E, et al. Iodine-131 total-body scan: localization of disseminated gastric adenocarcinoma. J Nucl Med 1984; 25: 1204-1209.
77. Yeh EL, Meade RC, Reutz PP. Radionuclide study of struma ovarii. J Nucl Med 1973; 14: 118-121.
78. You DL, Tzen KY, Chen JF, Kao PF, Tsai MF. False-positive whole-body iodine-131 scan due to intrahepatic duct dilatation. J Nucl Med 1997; 38: 1977-1979.
79. Zeissman HA, Bahar H, Fahey FH, Dubiansky V. Hepatic visualisation on iodine-131 whole-body thyroid scan. J Nucl Med 1987; 28: 1408-1411.
80. 131I ovarian uptake in a whole body scan for thyroid carcinoma. Semin Nucl Med 1989; 19: 340-342.
81. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II study). J Clin Endocrinol Metab 1994; 78: 188-196.
82. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337: 888-896.
83. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for detection of thyroid remnant or cancer. J Clin Endocrinol Metabol 1999; 84: 3877-3885.
84. Ladenson PW. Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Thyroid 1999; 9: 429-433.
85. Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nucl Med Commun 2000; 21: 521-528.
86. Riedel C, Dohan O, De La Vieja A, Gintes CS, Carrasco N. Journey of the iodide transporter NIS from its molecular identification to its clinical role in cancer. Trends Biochem Sci 2001; 26: 490-496.
87. 131I in the evaluation of differentiated thyroid cancers. J Nucl Med 1979; 20: 92-97.
88. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable thyroglobulin levels. J Nucl Med 1987; 28: 1888-1891.
89. Waxman A, Ramanna L, Chapman D, et al. The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation. J Nucl Med 1981; 22: 861-865.
90. 131I (i.e. it does not cause stunning in differentiated thyroid cancer). Nucl Med Commun 1997; 18: 505-512.
91. Fatourechi V, Hay ID, Mullan DP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000; 10: 573-577.
92. Park H-M, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodine on the uptake of ablative dose of iodine-131. Thyroid 1994; 4: 49-54.
93. 131I. J Nucl Med 2000; 41: 1198-1202.
94. Van Herle AJ, Uller RP, Matthews NL, et al. Radioimmunoassay for measurement of thyroglobulin in human subjects. J Clin Invest 1973; 52: 1320-1327.
95. Bayer MF, McDougall IR. Differences in thyroglobulin radioimmunoassays which affect management of thyroid cancer patients. Clin Chem 1984; 25: 402-405.
96. Ramana L, Waxman AD, Brachman MB, et al. Correlation of thyroglobulin measurements and radioiodine scans in the follow-up of patients with differentiated thyroid cancer. Cancer 1985; 55: 1525-1529.
97. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin antibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 1121-1127.
98. Van Wyngaarden KM, McDougall IR. Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue? Thyroid 1997; 7: 669-672.
99. Reiners C. Serum thyroglobulin determination for follow-up of differentiated thyroid cancer: Methods, limitations and clinical benefit. (Abstract) In: Thyroid One, Thyroid Cancer International Symposium, Linz, Austria. Thyroid 1998; 12: 1215.
100. Lubin E, Mechlis S, Zatz S, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnostic and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994; 35: 257-262.
101. Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual. Philadelphia: Lippincott-Raven, 1997.
102. Hay ID, Bergstrahl EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-1058.
103. Cady B. Our AMES is true: How an old concept still hits the mark. Or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997; 174: 462-468.
104. 131I therapy for elevated thyroglobulin levels. Thyroid 1997; 7: 273-276.
105. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metabol 1995; 80: 1488-1492.
106. 131I negative whole-body scan, and positive thyroglobulin in differentiated thyroid carcinoma: What is being treated? Thyroid 1997; 7: 669-672.
107. McDougall IR, Davidson J, Segall GM. Positron emission tomography and the thyroid with an emphasis on thyroid cancer. Nuclear Medicine Communications. 2001; 22: 485-492.